308 related articles for article (PubMed ID: 24014113)
1. IMD-0354 targets breast cancer stem cells: a novel approach for an adjuvant to chemotherapy to prevent multidrug resistance in a murine model.
Gomez-Cabrero A; Wrasidlo W; Reisfeld RA
PLoS One; 2013; 8(8):e73607. PubMed ID: 24014113
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously.
Hii LW; Chung FF; Soo JS; Tan BS; Mai CW; Leong CO
Breast Cancer Res Treat; 2020 Feb; 179(3):615-629. PubMed ID: 31784862
[TBL] [Abstract][Full Text] [Related]
4. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer.
Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC
Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581
[TBL] [Abstract][Full Text] [Related]
5. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
6. Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense.
Sun M; Yang C; Zheng J; Wang M; Chen M; Le DQS; Kjems J; Bünger CE
Acta Biomater; 2015 Dec; 28():171-182. PubMed ID: 26415776
[TBL] [Abstract][Full Text] [Related]
7. The novel inhibitor BRM270 downregulates tumorigenesis by suppression of NF-κB signaling cascade in MDR-induced stem like cancer-initiating cells.
Mongre RK; Sodhi SS; Ghosh M; Kim JH; Kim N; Park YH; Kim SJ; Heo YJ; Sharma N; Jeong DK
Int J Oncol; 2015; 46(6):2573-85. PubMed ID: 25872586
[TBL] [Abstract][Full Text] [Related]
8. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model.
Tiash S; Chowdhury EH
J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer.
Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R
Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609
[TBL] [Abstract][Full Text] [Related]
10. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
Erin N; Grahovac J; Brozovic A; Efferth T
Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
[TBL] [Abstract][Full Text] [Related]
11. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
12. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
[TBL] [Abstract][Full Text] [Related]
13. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer.
Lv L; Liu C; Chen C; Yu X; Chen G; Shi Y; Qin F; Ou J; Qiu K; Li G
Oncotarget; 2016 May; 7(22):32184-99. PubMed ID: 27058756
[TBL] [Abstract][Full Text] [Related]
14. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
Wang C; Wei X; Shao G
Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008
[TBL] [Abstract][Full Text] [Related]
15. pH-Responsive Polypropylene Sulfide Magnetic Nanocarrier-Mediated Chemo-Hyperthermia Kills Breast Cancer Stem Cells by Long-Term Reversal of Multidrug Resistance and Chemotherapy Resensitization.
Basu SM; Chauhan M; Giri J
ACS Appl Mater Interfaces; 2023 Dec; 15(50):58151-58165. PubMed ID: 38063494
[TBL] [Abstract][Full Text] [Related]
16. Salvianolic acid B reverses multidrug resistance in nude mice bearing human colon cancer stem cells.
Guo P; Wang J; Gao W; Liu X; Wu S; Wan B; Xu L; Li Y
Mol Med Rep; 2018 Aug; 18(2):1323-1334. PubMed ID: 29845279
[TBL] [Abstract][Full Text] [Related]
17. Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells.
Abdin SM; Tolba MF; Zaher DM; Omar HA
Chem Biol Interact; 2021 May; 340():109450. PubMed ID: 33775688
[TBL] [Abstract][Full Text] [Related]
18. Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin.
Saha S; Mukherjee S; Mazumdar M; Manna A; Khan P; Adhikary A; Kajal K; Jana D; Sa G; Mukherjee S; Sarkar DK; Das T
Transl Res; 2015 May; 165(5):558-77. PubMed ID: 25468484
[TBL] [Abstract][Full Text] [Related]
19. Active-targeting and acid-sensitive pluronic prodrug micelles for efficiently overcoming MDR in breast cancer.
Xu C; Xu J; Zheng Y; Fang Q; Lv X; Wang X; Tang R
J Mater Chem B; 2020 Apr; 8(13):2726-2737. PubMed ID: 32154530
[TBL] [Abstract][Full Text] [Related]
20. A multiple-targets alkaloid nuciferine overcomes paclitaxel-induced drug resistance in vitro and in vivo.
Liu RM; Xu P; Chen Q; Feng SL; Xie Y
Phytomedicine; 2020 Dec; 79():153342. PubMed ID: 32992085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
